Combined treatment with nafamostat mesilate and aspirin prevents heparin-induced thrombocytopenia in a hemodialysis patient.
We report on the management of a 36-year-old hemodialysis patient with heparin-induced thrombocytopenia (HIT, type II) and clot formation in extracorporeal circulation. Platelet aggregation test and measurement of anti-platelet factor 4/heparin complex antibody by enzyme-linked immunosorbent assay revealed to us that our patient had developed HIT. Instead of heparin, we used nafamostat mesilate (NM) as an anticoagulant during hemodialysis, but could not completely prevent HIT-induced thrombocytopenia or clot formation in the extracorporeal circuit. Combined use of NM and aspirin completely inhibited platelet aggregation, decrease in platelet count and clot formation in the extracorporeal circuit.
Takahashi
H
H
Department of Nephrology, Jichi Medical School, Tochigi, Japan.
Muto
S
S
Nakazawa
E
E
Yanagiba
S
S
Masunaga
Y
Y
Miyata
Y
Y
Tamba
K
K
Kusano
E
E
Matsuo
M
M
Matsuo
T
T
Asano
Y
Y
D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use*; D001550:Benzamidines; D005112:Extracorporeal Circulation; D006146:Guanidines / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000517:prevention & control*
D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D001241:Aspirin; C032855:nafamostat